Press Release: New data at AAN reinforce Novartis -3-

[34] Cohen J, et al. Long-term Effect of Fingolimod in Reducing Blood

Neurofilament Light Levels in Patients with Relapsing-remitting Multiple

Sclerosis. Poster presentation. 2019 AAN.

[35] Sormani M, et al. The Correlation of Blood Neurofilament Light

Chain with Brain Atrophy is Partly Independent from Inflammation. Oral

presentation. 2019 AAN.

[36] Hagemeier J, et al. The association between serum neurofilament

light chain and OCT measures in multiple sclerosis. Oral presentation.

2019 AAN.

[37] Jakimovski D, et al. Serum neurofilament light chain levels and

cognitive performance in multiple sclerosis: a longitudinal

retrospective 5-year study. Oral presentation. 2019 AAN.

[38] Tavazzi E, et al. The association between serum neurofilament

light chain, atrophied lesion volume and brain atrophy with disability

progression in multiple sclerosis. Poster presentation. 2019 AAN.

# # #

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Antonio Ligi Angela Fiorin

Novartis External Communications Novartis Global Pharma Communications

+41 79 723 3681 (mobile) +41 61 324 8631(direct)

antonio.ligi@novartis.com +41 79 752 6955 (mobile)

Eric Althoff angela.fiorin@novartis.com

Novartis US External Communications

+1 646 438 4335 eric.althoff@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 862 778 3275

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 862 778 3258

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media Release (PDF): http://hugin.info/134323/R/2243174/885517.pdf

This announcement is distributed by West Corporation on behalf of West

Corporation clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com

(END) Dow Jones Newswires

April 30, 2019 16:30 ET (20:30 GMT)